运动对治疗炎症性肠病的潜在益处:系统性审查
Ghadeer Sabir1, Hala A Abdelhady1, Adoum Oumar Abakar2,3
1Internal Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Cureus
|October 9, 2024
概括
运动显著改善了成人炎症性肠病 (IBD) 的生活质量,疾病活动和心理健康. 这一系统性审查强调运动是IBD患者有益的干预措施,尽管需要更多的研究.
科学领域:
- 胃肠病学 胃肠病学
- 运动医学 运动医学
- 公共卫生 公共卫生
背景情况:
- 炎症性肠病 (IBD) 显著影响成年人的生活质量.
- 运动是IBD管理的潜在治疗策略.
- 关于运动对IBD有效性的证据需要进行系统的评估.
研究的目的:
- 系统地审查运动对成人炎症性肠病 (IBD) 进展的影响.
- 评估运动作为IBD治疗方式的潜力.
- 综合符合PRISMA 2020指南的高质量研究结果.
主要方法:
- 按照PRISMA 2020指南进行系统审查.
- 在3个数据库和2个注册表中进行全面的文献搜索.
- 使用Cochrane RoB 2,NOS和JBI检查清单对12项高质量的研究进行质量评估.
主要成果:
- 运动干预措施对IBD成年人的心肺呼吸能力产生了积极影响.
- 观察到疾病活动,生活质量和心理健康的改善.
- 探索了各种运动方式,包括有氧,抵抗和心身.
结论:
- 运动对于患有炎症性肠病 (IBD) 的成年人来说是一个有益的干预措施.
- 个性化炼计划显示出增强IBD管理和患者结果的前景.
- 需要进一步的研究来优化运动处方和理解机制.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
323
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
323
Inflammatory Bowel Disease IV: Pharmacological Management
118
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
118
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
Inflammatory Bowel Disease V: Surgical Management
126
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
126
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
97
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
97
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117


